Crispr (clustered regularly interspaced short palindromic repeats) – is making headlines again. This time Systems Biology Institute at Yale are targeting cancer, metabolic disease, autoimmune disease, and neurological disorders.
“We have created four new Cas12a mouse lines that will allow researchers to study complex genetic interactions and their effects involved in many disorders,” said Sidi Chen, an associate professor of genetics and neurosurgery at Yale School of Medicine and a pioneer in the field of CRISPR technology. He is co-corresponding author of the new study.